AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie Inc. (NYSE:ABBV – Free Report) – Research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for shares of AbbVie in a research report issued to clients and investors ...

AbbVie expects full-year earnings in the range of $12.09 to $12.29 per share. AbbVie shares have increased 1.5% since the beginning of the year, while the S&P's 500 index has declined nearly 7%.

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.

ABBV earnings call for the period ending September 30, 2024.

Good morning, and welcome to AbbVie second quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms. Liz Shea, senior vice president, investor relations. Liz ...

AbbVie Inc. (NYSE:ABBV) Q2 2024 Earnings Conference Call July 25, 2024 9:00 AM ETCompany ParticipantsLiz Shea - Senior Vice President, Investor RelationsRob ...

AbbVie expects full-year earnings in the range of $10.71 to $10.91 per share. AbbVie shares have climbed 14% since the beginning of the year, while the S&P's 500 index has risen 14%.

AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and ...

AbbVie (NYSE: ABBV) just reported results for the second quarter of 2024. AbbVie reported earnings per share of $2.65. This was above the analyst estimate for EPS of $2.57.

AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?